1. Guy GP Jr, Miller GF, Legha JK, et al. Economic costs of chronic pain—United States, 2021. Med Care. 2025;63(9):679-685.

2. Schoenfeld AJ, Geiger J, Princic N, et al. Economic burden of managing acute and chronic pain in the United States: national estimates from 2022 data. Presented at: The International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; May 2024; Atlanta, GA.

3. Yong RJ, Mullins PM, Bhattacharyya N. Prevalence of chronic pain among adults in the United States. Pain. 2022;163(2):e328-e332.

4. Centers for Disease Control and Prevention. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR. 2022;71(3):1-95.

5. Cook CE, Rhon DI, Bialosky J, et al. Developing manual therapy frameworks for dedicated pain mechanisms. JOSPT Open. 2023;1(1):1-108.

6. Chimenti RL, Frey-Law LA, Sluka KA. A mechanism-based approach to physical therapist management of pain. Phys Ther. 2018;98(5):302-314.

7. Yam MF, Loh YC, Tan CS, Khadijah Adam S, Abdul Manan N, Basir R. General pathways of pain sensation and the major neurotransmitters involved in pain regulation. Int J Mol Sci. 2018;19(8):2164.

8. Cao B, Xu Q, Shi Y, et al. Pathology of pain and its implications for therapeutic interventions. Sig Transduct Target Ther. 2024;9:155.

9. : Liu S, Kelliher L. Physiology of pain—a narrative review on the pain pathway and its application in the pain management. DMR. 2022;5.

10. Cosio D. The perseverance loop: the psychology of pain and factors in pain perception. Pract Pain Manag. 2020;20(1).

11. McCarberg B, Peppin J. Pain pathways and nervous system plasticity: learning and memory in pain. Pain Med. 2019;20(12):2421-2437.

12. Nijs J, Leysen L, Vanlauwe, J, et al. Treatment of central sensitization in patients with chronic pain: time for change? Expert Opin Pharmacother. 2019;20(16):1961-1970.

13. Ji RR, Nackley A, Huh Y, et al. Neuroinflammation and central sensitization in chronic and widespread pain. Anesthesiology. 2018;129(2):343-366.

14. Smith HS, Kara DK, Argoff CE. Management of neuropathic pain: current insights and future perspectives. US Neurology. 2012;8(1):57-61.

15. Raffa RB, Pergolizzi JV Jr, Tallarida RJ. The determination and application of fixed-dose analgesic combinations for treating multimodal pain. J Pain. 2010;11(8):701-709.

16. Kulkantrakorn K. Emerging concepts and treatment in neuropathic pain. Neurology Asia. 2012;17:265-271.

17. Voscopoulos C, Lema M. When does acute pain become chronic? Br J Anaesth. 2010;105(S1):i69-i85.

18. European Urological Association. Guidelines on Pain Management and Palliative Care. Available at https://d56bochluxqnz.cloudfront.net/media/Pocket-Pain-Management-Urology_LR.pdf. Last accessed October 1, 2025.

19. Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S5.

20. Whittle SL, Colebatch AN, Buchbinder R, et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology. 2012;51:1416-1425.

21. Xu B, Descalzi G, Ye HR, Zhuo M, Wang YW. Translational investigation and treatment of neuropathic pain. Mol Pain. 2012;8:15.

22. Barkin RL, Barkin SJ, Barkin DS. Pharmacotherapeutic management of pain with a focus directed at the geriatric patient. Rheum Dis Clin North Am. 2007;33(1):1-31.

23. Rahman W, D'Mello R, Dickenson AH. Peripheral nerve injury-induced changes in spinal alpha(2)-adrenoceptor-mediated modulation of mechanically evoked dorsal horn neuronal responses. J Pain. 2008;9:350-359.

24. Marks DM, Shah MJ, Patkar AA, et al. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Cur Neuropharmacology. 2009;7(4):331-336.

25. Blonk MI, Koder BG, van den Bemt P, Huygen FJ. Use of oral ketamine in chronic pain management: a review. Eur J Pain. 2009;14(5):466-472.

26. Patil S, Anitescu M. Efficacy of outpatient ketamine infusions in refractory chronic pain syndromes: a 5-year retrospective analysis. Pain Med. 2012;13(2):263-269.

27. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo-controlled study. Pain. 2009;147(1-3):107-115.

28. Dinakar P. Pain management. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ (eds). Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Philadelphia, PA: Saunders; 2021.

29. Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician. 2013;16(1):27-40.

30. Aggarwal SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. Clin J Pain. 2013;29(2):162-171.

31. Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain. 2013;29(10):857-864.

32. Costigan M, Latremoliere A, Woolf CJ. Analgesia by inhibiting tetrahydrobiopterin synthesis. Curr Opin Pharmacol. 2012;12(1): 92-99.

33. McCleane GJ, Suzuki R, Dickenson AH. Does a single intravenous injection of the 5HT3 receptor antagonist ondansetron have an analgesic effect in neuropathic pain? A double-blinded, placebo-controlled cross-over study. Anesth Analg. 2003;97(5):1474-1478.

34. Stevans JM, Saper RB. Chronic low back pain. In: Rakel D, Minichiello V (eds). Integrative Medicine. 5th ed. Philadelphia, PA: Saunders; 2022.

35. Balagué F, Mannion AF, Pellisé F, Cedraschi C. Nonspecific low back pain. Lancet. 2012;379(9814):482-491.

36. Flor H. New developments in the understanding and management of persistent pain. Curr Opin Psychiatry. 2012;25(2):109-113.

37. Haanpää M, Hietaharju A. Central neuropathic pain. In: Kopf A, Patel NB (eds). Guide to Pain Management in Low-Resource Settings. Seattle, WA: IASP Press; 2010: 207-212.